ADC Therapeutics 株価情報 (NYSE: ADCT)

最新ニュース ADC Therapeutics (NYSE:ADCT) 株価情報

ADC Therapeutics

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.

ADC Therapeutics SA

Activist JCP Investment Management is proposing a spinoff of some brands.
 <a href="https://www.axios.com/pro/retail-deals/2024/11/12/cheesecake-factory-jcp-strategic-pe-buyers" title="https://www.axios.com/pro/retail-deals/2024/11/12/cheesecake-factory-jcp-strategic-pe-buyers">https://www.axios.com/pro/retail-deals/2024/11/12/cheesecake-factory-jcp-strategic-pe-buyers</a>

News

Trading Ideas

CAKE

'Cheesecake Factory's strategic options for its smaller brands' - Axios

WIIM

ABSI

Absci shares are trading lower after the company reported worse-than-expected Q3 financial results.

ASPN

Aspen Aerogels shares are trading lower after Barclays cut its price target on the stock from $27 to $25.

TIGR

UP Fintech shares are trading lower after the company reported worse-than-expected Q3 adjusted EPADS results.

DADA

Dada Nexus shares are trading lower. Mizuho cut its price target on the stock from $4.5 to $4.

Recent innovations in <a href="https://www.benzinga.com/topic/psychedelics-research">psychedelics research</a> are laying the groundwork for a potential breakthrough in <a href="https://www.benzinga.com/topic/psychedelic-assisted-therapies">mental health treatments</a>. The focus is on three new compounds patented by CaaMTech, Inc., designed to address the limitations of traditional psychedelics such as <a href="https://www.benzinga.com/topic/psilocybin">psilocybin</a> and <a href="https://www.benzinga.com/topic/psilocin">psilocin</a>. 
According to a <a href="https://pubs.acs.org/doi/10.1021/acsmedchemlett.4c00519">patent review</a> published by the American Chemical Society, the new compounds promise improved stability, bioavailability and therapeutic efficacy for conditions such as depression, anxiety and substance use disorders.
<h3 class="wp-block-heading">Revolutionizing Psilocin Delivery: A New Approach </h3>
A groundbreaking patent, <a href="https://patents.google.com/patent/US20230406823A1/en?oq=US+2023%2f0406823+A1">US 2023/0406823 A1</a>, introduces a new compound called 4-pivaloyloxy-N-methyltryptammonium chloride, designed to solve some of the biggest challenges in using psilocin for therapeutic purposes. Psilocin, a chemical related to psilocybin, the psychoactive compound in <a href="https://www.benzinga.com/topic/magic-mushrooms">magic mushrooms</a>, affects mood, perception and cognition by interacting with serotonin receptors in the brain. However, psilocin is unstable, which has limited its use in medicine.
The key innovation here is a stable form of psilocin that, when taken, is gradually broken down into active psilocin in the body. This prodrug allows for a controlled release of its effects, making it easier to use in medical treatments. Early studies show that this new compound is more stable and easier for the body to absorb, making it a promising option for consistent therapeutic effects. It could also improve patient adherence to treatment, especially in oral forms of medication.
<h3 class="wp-block-heading">Improving Stability And Effectiveness: Alkyl Quaternary Ammonium Tryptamines</h3>
Another important patent, <a href="https://patents.google.com/patent/US20240116867A1/en?oq=US+2024%2f0116867+A1">US 2024/0116867 A1</a>, presents a new group of compounds called alkyl quaternary ammonium tryptamines. These compounds are designed to be more stable and easier to dose than traditional psilocybin. By modifying the chemical structure, these compounds bind more effectively to serotonin receptors, especially the 5-HT2A receptor, which is responsible for the psychoactive effects of psychedelics.
Preclinical research shows that these new compounds retain the therapeutic benefits of psilocybin but have better pharmacokinetic properties, meaning they are absorbed, distributed and broken down by the body in a more controlled way. They could become valuable alternatives to traditional psychedelics, offering improved stability and effectiveness for mental health treatments.
<h3 class="wp-block-heading">Advancing Prodrug Technologies: 4-Pivaloyloxy-N-Methyltryptammonium Derivatives</h3>
Another patent, <a href="https://patents.google.com/patent/WO2023240104A1/en?oq=WO+2023%2f240104+A1">WO 2023/240104 A1</a>, goes further into developing variations of 4-pivaloyloxy-N-methyltryptammonium compounds as prodrugs for psilocin and similar substances. These derivatives are engineered to improve how well the body absorbs and utilizes the active ingredients, ensuring a more predictable and consistent response to treatment.
These advancements aim to address issues like rapid breakdown of the drug and inconsistent absorption, which can make therapeutic use of psilocin unpredictable. The goal is to create prodrugs that provide more reliable, controlled outcomes, especially in treating serious mental health conditions.
<h3 class="wp-block-heading">Implications For Psychedelic-Assisted Therapy</h3>
These patent innovations represent a major step forward in psychedelic therapy by improving how psilocin and related compounds are absorbed and processed in the body. Early studies show promising results, suggesting these new drugs could offer more effective and reliable treatments for mental health and neurological conditions. As research progresses, these breakthroughs may transform mental health care, providing new hope for patients with treatment-resistant conditions. The focus on improving stability, bioavailability and effectiveness underscores the importance of continued innovation in psychedelic medicine.
<h3 class="wp-block-heading">Moving Toward Clinical Trials</h3>
While the early research is promising, the next step is to conduct thorough clinical trials to test the compounds&#8217; safety and effectiveness in humans. Encouraging results so far suggest that these new prodrugs could represent a fresh type of therapy that combines the benefits of traditional medications with the potential of psychedelic-assisted treatments.
<h3 class="wp-block-heading">Industry Outlook</h3>
The increasing number of patent filings and breakthroughs in psychedelic research reflects growing interest in new mental health treatments. Companies are developing innovative compounds that could revolutionize the treatment of mental and neurological conditions. By focusing on prodrugs and chemical derivatives, these advancements aim to overcome the challenges that have limited psychedelics&#8217; medical use. Improved stability and bioavailability could make these new compounds viable alternatives to current treatments, especially for conditions that are difficult to manage with existing medications.
Cover image made with AI

Cannabis

Psychedelics

Health Care

Patents Reveal New Prodrugs For Psilocin, Promising Reliable Mental Health Treatments

Deep-pocketed investors have adopted a bullish approach towards FedEx (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in FDX usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 8 extraordinary options activities for FedEx. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 37% leaning bullish and 37% bearish. Among these notable options, 4 are puts, totaling $204,822, and 4 are calls, amounting to $180,133.
<h3>What's The Price Target?</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $240.0 and $300.0 for FedEx, spanning the last three months.
<h3>Volume &amp; Open Interest Trends</h3>
In today's trading context, the average open interest for options of FedEx stands at 797.71, with a total volume reaching 408.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in FedEx, situated within the strike price corridor from $240.0 to $300.0, throughout the last 30 days.
<h3>FedEx Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731439895_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>FDX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$16.25</td>
<td>$15.75</td>
<td>$15.75</td>
<td>$250.00</td>
<td>$92.9K</td>
<td>325</td>
<td align="right">59</td>
</tr>
<tr>
<td>FDX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$14.25</td>
<td>$14.2</td>
<td>$14.25</td>
<td>$290.00</td>
<td>$61.1K</td>
<td>2.7K</td>
<td align="right">293</td>
</tr>
<tr>
<td>FDX</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/19/25</td>
<td>$32.2</td>
<td>$31.6</td>
<td>$31.92</td>
<td>$290.00</td>
<td>$47.8K</td>
<td>141</td>
<td align="right">15</td>
</tr>
<tr>
<td>FDX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$21.9</td>
<td>$21.5</td>
<td>$21.9</td>
<td>$300.00</td>
<td>$41.6K</td>
<td>1.5K</td>
<td align="right">24</td>
</tr>
<tr>
<td>FDX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/18/26</td>
<td>$52.05</td>
<td>$51.5</td>
<td>$51.5</td>
<td>$290.00</td>
<td>$41.2K</td>
<td>35</td>
<td align="right">15</td>
</tr>
</tbody>
</table>

<h3>About FedEx</h3>
FedEx pioneered overnight delivery in 1973 and remains the world's largest express package provider. In its fiscal 2024, which ended in May, FedEx derived 47% of revenue from its express division, 37% from ground, and 10% from freight, its asset-based less-than-truckload shipping segment. The remainder came from other services, including FedEx Office, which provides document production/shipping, and FedEx Logistics, which provides global forwarding. FedEx acquired Dutch parcel delivery firm TNT Express in 2016, boosting its presence across Europe. TNT was previously the fourth-largest global parcel delivery provider.
In light of the recent options history for FedEx, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Present Market Standing of FedEx</h3>
<ul>
<li>With a trading volume of 610,647, the price of FDX is up by 0.38%, reaching $290.9.</li>
<li>Current RSI values indicate that the stock is may be overbought.</li>
<li>Next earnings report is scheduled for 37 days from now.</li>
</ul>
<h3>What Analysts Are Saying About FedEx</h3>
Over the past month, 1 industry analysts have shared their insights on this stock, proposing an average target price of $331.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Citigroup continues to hold a Buy rating for FedEx, targeting a price of $331. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for FedEx, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Markets

FedEx Unusual Options Activity For November 12

Investors with a lot of money to spend have taken a bullish stance on Twilio (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TWLO#NYSE">TWLO</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with TWLO, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 28 uncommon options trades for Twilio.
This isn't normal.
The overall sentiment of these big-money traders is split between 39% bullish and 39%, bearish.
Out of all of the special options we uncovered, 2 are puts, for a total amount of $70,258, and 26 are calls, for a total amount of $1,721,641.
<h3>What's The Price Target?</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $62.5 and $130.0 for Twilio, spanning the last three months.
<h3>Volume &amp; Open Interest Trends</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Twilio's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Twilio's substantial trades, within a strike price spectrum from $62.5 to $130.0 over the preceding 30 days.
<h3>Twilio Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731439860_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TWLO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>11/15/24</td>
<td>$29.8</td>
<td>$29.0</td>
<td>$29.8</td>
<td>$67.50</td>
<td>$283.1K</td>
<td>4.2K</td>
<td align="right">100</td>
</tr>
<tr>
<td>TWLO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$14.75</td>
<td>$13.55</td>
<td>$14.65</td>
<td>$95.00</td>
<td>$146.5K</td>
<td>2.1K</td>
<td align="right">168</td>
</tr>
<tr>
<td>TWLO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$6.25</td>
<td>$6.1</td>
<td>$6.1</td>
<td>$95.00</td>
<td>$104.3K</td>
<td>2.4K</td>
<td align="right">209</td>
</tr>
<tr>
<td>TWLO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/29/24</td>
<td>$6.35</td>
<td>$5.85</td>
<td>$6.3</td>
<td>$93.00</td>
<td>$94.5K</td>
<td>1.4K</td>
<td align="right">317</td>
</tr>
<tr>
<td>TWLO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/29/24</td>
<td>$6.3</td>
<td>$6.15</td>
<td>$6.3</td>
<td>$93.00</td>
<td>$90.0K</td>
<td>1.4K</td>
<td align="right">472</td>
</tr>
</tbody>
</table>

<h3>About Twilio</h3>
Twilio is a cloud-based communications platform-as-a-service company offering communication building blocks that allow for a fully customized customer engagement experience spanning voice, video, chat, and SMS messaging. It does this through various application programming interfaces and prebuilt solution applications aimed at improving customer engagement. The company leverages its Super Network, a global network of carrier relationships, to facilitate high-speed, cost-effective communication.
After a thorough review of the options trading surrounding Twilio, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Present Market Standing of Twilio</h3>
<ul>
<li>With a volume of 3,030,892, the price of TWLO is up 3.43% at $97.28. </li>
<li>RSI indicators hint that the underlying stock may be overbought.</li>
<li>Next earnings are expected to be released in 92 days.</li>
</ul>
<h3>Professional Analyst Ratings for Twilio</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $82.8.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Wells Fargo persists with their Equal-Weight rating on Twilio, maintaining a target price of $80. 
&#x2A; An analyst from Oppenheimer has decided to maintain their Outperform rating on Twilio, which currently sits at a price target of $85. 
&#x2A; Consistent in their evaluation, an analyst from Mizuho keeps a Neutral rating on Twilio with a target price of $70. 
&#x2A; Consistent in their evaluation, an analyst from TD Cowen keeps a Hold rating on Twilio with a target price of $85. 
&#x2A; An analyst from Piper Sandler persists with their Overweight rating on Twilio, maintaining a target price of $94. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Twilio with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

TWLO

Twilio's Options: A Look at What the Big Money is Thinking

U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling more than 200 points on Tuesday.
The Dow traded down 0.54% to 44,053.04 while the NASDAQ fell 0.01% to 19,299.60. The S&amp;P 500 also fell, dropping, 0.09% to 5,995.74.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/short-ideas/24/11/41874548/top-4-health-care-stocks-that-may-plunge-this-quarter">Top 4 Health Care Stocks That May Plunge This Quarter</a>
Leading and Lagging Sectors Communication services shares surged by 0.5% on Tuesday.
In trading on Tuesday, materials shares fell by 1.4%.
Top Headline
Home Depot Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HD#NYSE">HD</a>) reported better-than-expected third-quarter earnings and lifted its full-year 2024 outlook.
HD reported third-quarter sales growth of 6.6% year-over-year to $40.217 billion, beating the consensus estimate of $39.173 billion. Adjusted EPS was $3.78 (-1.8% year over year), beating the consensus of $3.64.
Home Depot raised its sales guidance from $156.49 billion – $158.01 billion to $158.78 billion versus the $157.33 billion consensus. It expects comparable sales to decline approximately ~2.5% (prior expected to decline 3% – 4%).
HD now expects adjusted EPS of $15.10 (representing decline of approximately 1% from $15.25 in FY23) versus the consensus of $14.84. The company sees a gross margin of ~33.5% and an adjusted operating margin of 13.8%.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>BTC Digital Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTCT#NASDAQ">BTCT</a>) shares shot up 379% to $12.07 after gaining around 36% on Monday.</li>
<li>Shares of Genius Group Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GNS#NYSE">GNS</a>) got a boost, surging 74% to $1.0950 after the company announced the adoption of a Bitcoin treasury reserve strategy, with Bitcoin as its primary treasury reserve asset.</li>
<li>Taysha Gene Therapies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSHA#NYSE">TSHA</a>) shares were also up, gaining 39% to $2.2650. Needham reiterated a Buy rating on the stock and Cantor Fitzgerald reiterated an Overweight rating.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Neurogene Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NGNE#NASDAQ">NGNE</a>) shares dropped 47% to $37.98. The company issued interim efficacy data from its first four low-dose pediatric participants in NGN-401 gene therapy clinical trial for Rett Syndrome.</li>
<li>Shares of Pagaya Technologies Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGY#NASDAQ">PGY</a>) were down 35% to $10.99 after the company reported third-quarter results.</li>
<li>Autozi Internet Technology (Global) Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZI#NASDAQ">AZI</a>) was down, falling 30% to $2.02.</li>
</ul>
Commodities In commodity news, oil traded up 0.1% to $68.10 while gold traded down 0.5% at $2,605.40.
Silver traded up 0.5% to $30.790 on Tuesday, while copper fell 1.9% to $4.1465.
Euro zone
European shares closed lower today. The eurozone's STOXX 600 tumbled 1.98%, Germany's DAX fell 2.13% and France's CAC 40 tumbled 2.69%. Spain's IBEX 35 Index fell 1.85%, while London's FTSE 100 dipped 1.22%.
Asia Pacific Markets
Asian markets closed lower on Tuesday, with Japan's Nikkei 225 falling 0.40%, Hong Kong's Hang Seng Index falling 2.84%, China's Shanghai Composite Index dipping 1.39% and India's BSE Sensex falling 1.03%.
Economics
<ul>
<li>U.S. consumer inflation expectations for the year ahead eased to 2.9% in October compared to 3% in each of the prior four months.</li>
<li>The RealClearMarkets/TIPP Economic Optimism Index rose 13.4% in November to a reading of 53.2, recording the highest reading in over three years.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/11/41914949/this-nvidia-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-tuesday">This Nvidia Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday</a></li>
</ul>

Earnings

Equities

Eurozone

Commodities

BTCT

NGNE

TSHA

Dow Dips Over 200 Points; Home Depot Posts Upbeat Earnings

Deep-pocketed investors have adopted a bullish approach towards ASML Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASML#NASDAQ">ASML</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in ASML usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 49 extraordinary options activities for ASML Holding. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 51% leaning bullish and 24% bearish. Among these notable options, 14 are puts, totaling $1,088,940, and 35 are calls, amounting to $3,350,071.
<h3>What's The Price Target?</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $270.0 to $1000.0 for ASML Holding over the last 3 months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in ASML Holding's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to ASML Holding's substantial trades, within a strike price spectrum from $270.0 to $1000.0 over the preceding 30 days.
<h3>ASML Holding Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731439854_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ASML</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$323.7</td>
<td>$312.5</td>
<td>$315.27</td>
<td>$360.00</td>
<td>$315.2K</td>
<td align="right">7</td>
<td align="right">10</td>
</tr>
<tr>
<td>ASML</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/18/26</td>
<td>$235.3</td>
<td>$230.4</td>
<td>$233.3</td>
<td>$860.00</td>
<td>$233.3K</td>
<td align="right">31</td>
<td align="right">10</td>
</tr>
<tr>
<td>ASML</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$409.9</td>
<td>$401.6</td>
<td>$407.95</td>
<td>$270.00</td>
<td>$203.9K</td>
<td align="right">62</td>
<td align="right">10</td>
</tr>
<tr>
<td>ASML</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$400.0</td>
<td>$391.7</td>
<td>$398.13</td>
<td>$280.00</td>
<td>$199.0K</td>
<td align="right">36</td>
<td align="right">5</td>
</tr>
<tr>
<td>ASML</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$376.2</td>
<td>$369.2</td>
<td>$374.75</td>
<td>$300.00</td>
<td>$187.3K</td>
<td align="right">46</td>
<td align="right">10</td>
</tr>
</tbody>
</table>

<h3>About ASML Holding</h3>
ASML is the leader in photolithography systems used in the manufacturing of semiconductors. Photolithography is the process in which a light source is used to expose circuit patterns from a photo mask onto a semiconductor wafer. The latest technological advances in this segment allow chipmakers to continually increase the number of transistors on the same area of silicon, with lithography historically representing a high portion of the cost of making cutting-edge chips. ASML outsources the manufacturing of most of its parts, acting like an assembler. ASML's main clients are TSMC, Samsung, and Intel.
Following our analysis of the options activities associated with ASML Holding, we pivot to a closer look at the company's own performance.
<h3>Present Market Standing of ASML Holding</h3>
<ul>
<li>Currently trading with a volume of 1,016,697, the ASML's price is up by 0.33%, now at $673.55. </li>
<li>RSI readings suggest the stock is currently may be approaching oversold.</li>
<li>Anticipated earnings release is in 78 days.</li>
</ul>
<h3>Professional Analyst Ratings for ASML Holding</h3>
A total of 3 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $917.6666666666666.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Bernstein keeps a Outperform rating on ASML Holding with a target price of $815. 
&#x2A; An analyst from JP Morgan has decided to maintain their Overweight rating on ASML Holding, which currently sits at a price target of $1148. 
&#x2A; Maintaining their stance, an analyst from Wells Fargo continues to hold a Overweight rating for ASML Holding, targeting a price of $790. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for ASML Holding, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

ASML

Behind the Scenes of ASML Holding's Latest Options Trends

The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and the NASDAQ Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) have seen impressive gains since Donald Trump&#8216;s <a href="https://www.benzinga.com/news/24/11/41768178/donald-trump-defeats-kamala-harris-to-win-2024-election">election win on Nov. 5</a>. 
Wednesday&#8217;s AAII Sentiment survey could reveal exactly how bullish the market is on Trump&#8217;s second term.
Recent Data: Sentiment has waned slightly since the summer and spring. Investors in 2024 were most bullish in July —52.75% responded as such on July 17.
The Nov. 6 <a href="https://www.aaii.com/sentimentsurvey/sent_results">reading</a> of the survey, a day after the election, found 41.5% of participants bullish on the market, slightly higher than 39.5% on Oct. 30. The most recent data point may not be accounting for all the shift in investor opinion.
The next AAII report, set to be released Wednesday, could paint a fuller picture of investors&#8217; reactions to Trump&#8217;s win.
Historical Data: Following Trump&#8217;s win in 2016, investor confidence markedly increased. The percentage of respondents bullish on the economy catapulted from 23.64% to 49.89% in the three weeks following the election. This elevated bullishness subsided in the following months.
Investors were seemingly happy when Trump lost reelection to Joe Biden in 2020 — investor bullishness rose from 35.29% to 55.84%.
An opposite effect was observed during Barack Obama&#8216;s election wins over Mitt Romney in 2012 and John McCain in 2008. Investors became more bullish following George W. Bush&#8216;s 2004 election win against John Kerry.
Why it Matters: Trump&#8217;s second administration is <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41798981/jim-cramer-calls-trumps-return-to-white-house-a-huge-win-for-the-stock-market">seen by many traders as a boon for the stock market</a>. 
The promise of deregulation and lower tax rates for corporates could be two tailwinds for big businesses, though his embrace of oil and protectionist trade policies have <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41880110/solar-renewables-stocks-crash-after-trump-win-should-you-buy-now-at-cheap-valuations">already hurt certain stocks</a>. 
Economists warn that <a href="https://www.benzinga.com/news/24/11/41737933/trump-tariff-proposed-may-cost-americans-78b-in-spending-study">American consumers</a>, especially low-income families, will also end up paying more for everyday goods. 
Also Read:
<ul>
<li><a href="https://www.benzinga.com/24/11/41909966/shell-wins-appeal-against-landmark-climate-ruling-dodging-major-emission-cut-mandate">Shell Wins Appeal Against Landmark Climate Ruling, Dodging Major Emission Cut Mandate</a></li>
</ul>
Image: Shutterstock

Government

Politics

Economics

Just How Bullish Is The Market On Trump's Election Win? To Find Out, Look To The Past

The Kansas City Chiefs are the only unbeaten NFL team remaining in the 2024 season and are the betting favorites to be the first team to win back-to-back-to-back Super Bowls <a href="https://www.benzinga.com/general/entertainment/24/02/37080383/three-peat-super-bowl-lix-odds-kansas-city-chiefs-back-to-back-to-back-payout">in NFL history.</a>
Here's a look at the current betting odds after the midway point of the 2024 NFL season and how it compares to the start of the season.
What Happened: The<a href="https://www.benzinga.com/topic/nfl"> National Football League</a> has wrapped 10 weeks of the 2024 season and with each team playing 17 games across 18 weeks, every team has now played at least nine of their 17 games in the season.
With teams all past the midway of their 17 games, here's a look at the current betting odds to win Super Bowl LIX from sportsbook DraftKings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>) and how the odds compare to back in February in parentheses after the Chiefs won their second straight Super Bowl.
<ul>
<li>Kansas City Chiefs, 9-0: +400 (+650, 2nd)</li>
<li>Detroit Lions, 8-1: +450 (+1,200, 5th)</li>
<li>Baltimore Ravens, 7-3: +600 (+900, 3rd)</li>
<li>Buffalo Bills, 8-2: +800 (+1,000, 4th)</li>
<li>Philadelphia Eagles, 7-2: +900 (+2,000, 8th)</li>
<li>San Francisco 49ers, 5-4: +1,000 (+550, 1st)</li>
<li>Minnesota Vikings, 7-2: +2,200 (Not in top 13)</li>
<li>Washington Commanders, 7-3: +2,500 (Not in top 13)</li>
<li>Pittsburgh Steelers, 7-2: +2,500 (Not in top 13)</li>
<li>Green Bay Packers, 6-3: +2,500 (+2,000, 9th)</li>
<li>Houston Texans, 6-4: +2,800 (+2,200, 11th)</li>
<li>Los Angeles Chargers, 6-3: +3,500 (+2,500, 13th)</li>
<li>Arizona Cardinals, 6-4: +4,000 (Not in top 13)</li>
<li>Cincinnati Bengals, 4-6: +4,500 (+1,300, 6th)</li>
<li>Atlanta Falcons, 6-4: +5,000 Not in top 13)</li>
</ul>
The list of the top 15 favorite teams includes five that were not among the top 13 favorites back in February. The 49ers, the betting favorites, fell to sixth with a 5-4 record. The Bengals, which had the sixth-best odds in February, fell to 14th and the only team with a losing record to be among the 15 favorites. The Lions and Eagles have moved up several places thanks to strong starts.
The 2024 NFL season could see a first-time Super Bowl winner and could even include a team that has never been to a Super Bowl. The Lions and Texans are two of the<a href="https://www.benzinga.com/general/sports-betting/24/09/40720484/which-4-teams-have-never-reached-the-super-bowl-betting-payouts-if-history-is-made-in-2024"> four teams that have never been </a>to a Super Bowl and both are among the 15 current favorites with the Lions ranked a narrow second behind the Chiefs.
The Bills, Vikings, Chargers, Cardinals, Bengals and Falcons have all been to a Super Bowl but never won, with the Bills and Vikings each having a 0-4 record in career Super Bowls.
Dropping out of the top 13 for odds were the Miami Dolphins (7th), Dallas Cowboys (10th) and New York Jets (12th), which have records of 3-6, 3-6 and 3-7, respectively.
Strong TV Ratings: The 2024 NFL season witnessed some big primetime television matchups and key rivalries that helped boost viewership.
Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), which hosts "Thursday Night Football," is seeing its best ratings with an average of 13 million viewers through week 9, up 4% year-over-year and ahead of averages of 11.86 million in the 2023 season and 9.58 million in the 2022 season, as reported by <a href="https://frontofficesports.com/nfl-tv-ratings-can-amazon-keep-up-record-tnf-pace/">FrontOfficeSports</a>.
Fox Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOX#NASDAQ">FOX</a>)(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOXA#NASDAQ">FOXA</a>) is averaging 18.65 million viewers for its Sunday games, the company's highest average through week 9 since 2016.
Of the 10 most-watched NFL games for the season, five were on FOX, three were on Paramount Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PARA#NASDAQ">PARA</a>)(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PARAA#NASDAQ">PARAA</a>)-owned CBS and two were on Comcast Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCSA#NASDAQ">CMCSA</a>)-owned NBC. The most-watched game to date is the Week 1 Chiefs vs. Ravens matchup on NBC with 29.2 million viewers, as <a href="https://www.nytimes.com/athletic/5902219/2024/11/08/chiefs-cowboys-tv-ratings-americas-team/">reported </a>by Action Network.
The Chiefs have been featured in six of the most-watched NFL games for the 2024 season.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/entertainment/24/05/38625265/heres-how-much-a-super-bowl-lix-commercial-will-cost-how-fox-corporation-stock-could-benefi">Here&#8217;s How Much A Super Bowl LIX Commercial Will Cost, How Fox Corporation Stock Could Benefit</a></li>
</ul>
Photo: Shutterstock

Sports Betting

Sports

AMZN

CMCSA

DKNG

FOXA

PARA

PARAA

Super Bowl LIX Betting Odds: Kansas City Chiefs Favorite To Three-Peat, Can Detroit Lions Spoil The Party, Make Team History?

ACTG

Acacia Research shares are trading lower after the company reported worse-than-expected Q3 revenue results.

SATS

EchoStar shares are trading lower after the company reported worse-than-expected Q3 EPS and revenue.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Needham boosted the price target for monday.com Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDY#NASDAQ">MNDY</a>) from $300 to $350. Needham analyst Scott Berg maintained a Buy rating. monday.com shares closed at $275.21 on Monday. <a href="https://www.benzinga.com/quote/MNDY/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Ascendiant Capital raised the price target for Myomo, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MYO#NYSE">MYO</a>) from $8.5 to $9. Ascendiant Capital analyst Edward Woo maintained a Buy rating. Myomo shares closed at $4.90 on Monday. <a href="https://www.benzinga.com/quote/MYO/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HC Wainwright &amp; Co cut Phunware, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHUN#NASDAQ">PHUN</a>) price target from $9 to $6. HC Wainwright &amp; Co. analyst Scott Buck downgraded the stock from Buy to Neutral. Phunware shares settled at $5.99 on Monday. <a href="https://www.benzinga.com/quote/PHUN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities raised iHeartMedia, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IHRT#NASDAQ">IHRT</a>) price target from $1 to $3. B of A Securities analyst Jessica Reif Cohen upgraded the stock from Underperform to Neutral. iHeartMedia shares closed at $2.49 on Monday. <a href="https://www.benzinga.com/quote/IHRT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Deutsche Bank boosted SentinelOne, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/S#NYSE">S</a>) price target from $25 to $32. Deutsche Bank analyst Brad Zelnick upgraded the stock from Hold to Buy. SentinelOne shares closed at $27.18 on Monday. <a href="https://www.benzinga.com/quote/S/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Needham boosted Autolus Therapeutics plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUTL#NASDAQ">AUTL</a>) price target from $9 to $10. Needham analyst Gil Blum maintained a Buy rating. Autolus Therapeutics shares closed at $3.51 on Monday. See how other analysts view this stock.</li>
<li>Keefe, Bruyette &amp; Woods increased the price target for Horace Mann Educators Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HMN#NYSE">HMN</a>) from $39 to $44. Keefe, Bruyette &amp; Woods analyst Meyer Shields downgraded the stock from Outperform to Market Perform. Horace Mann Educators shares settled at $42.31 on Monday. <a href="https://www.benzinga.com/quote/HMN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley slashed International Flavors &amp; Fragrances Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IFF#NYSE">IFF</a>) price target from $111 to $110. Morgan Stanley analyst Lisa De Neve upgraded the stock from Equal-Weight to Overweight. International Flavors shares closed at $91.21 on Monday. <a href="https://www.benzinga.com/quote/IFF/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Mizuho raised the price target for NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) from $140 to $165. Mizuho analyst Vijay Rakesh maintained an Outperform rating. NVIDIA shares closed at $145.26 on Monday. <a href="https://www.benzinga.com/quote/NVDA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup increased Saia, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIA#NASDAQ">SAIA</a>) price target from $534 to $651. Citigroup analyst Ariel Rosa maintained a Buy rating. Saia shares closed at $558.10 on Monday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Read This Next:
<ul>
<li> <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41877638/jim-cramer-tech-stock-go-to-160-recommends-buying-dominos-pizza">Jim Cramer: This Tech Stock Can &#8216;Go To 160,&#8217; Recommends Buying Domino&#8217;s Pizza</a></li>
</ul>

Price Target

Analyst Ratings

AUTL

IHRT

MNDY

NVDA

PHUN

SAIA

Nvidia To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Tuesday

U.S. stocks were lower, with the Dow Jones index falling more than 200 points on Tuesday.
Shares of Tyson Foods, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSN#NYSE">TSN</a>) rose sharply during Monday's session following <a href="https://www.benzinga.com/news/earnings/24/11/41900813/tyson-foods-q4-earnings-revenue-and-eps-beat-beef-gains-outshine-chicken-dip-more">upbeat quarterly earnings</a>.
The company reported fourth-quarter adjusted earnings per share of 92 cents beating the street view 69 cents. Quarterly revenues of $13.565 billion (+1.6%) outpaced the analyst consensus of $13.392 billion.
Tyson shares jumped 8.5% to close at $63.79 on Monday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Taysha Gene Therapies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSHA#NASDAQ">TSHA</a>) shares surged 39.8% to $2.2781. Needham reiterated a Buy rating on the stock and Cantor Fitzgerald reiterated an Overweight rating.</li>
<li>NWTN Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWTN#NASDAQ">NWTN</a>) gained 33.6% to $1.5827.</li>
<li>Altimmune, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>) rose 30.2% to $9.57 after the company reported better-than-expected third-quarter financial results. Also, UBS initiated coverage on the stock with a Buy rating and announced a price target of $26.</li>
<li>Shopify Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHOP#NYSE">SHOP</a>) gained 25.5% to $112.97 following strong quarterly sales.</li>
<li>Revance Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVNC#NASDAQ">RVNC</a>) rose 19% to $4.1300.</li>
<li>Priority Technology Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTH#NASDAQ">PRTH</a>) gained 16.7% to $8.63.</li>
<li>Alight, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALIT#NYSE">ALIT</a>) shares rose 13.6% to $8.48 after the company reported better-than-expected third-quarter sales results and issued fourth-quarter adjusted EPS guidance with its midpoint above estimates..</li>
<li>Grab Holdings Limite (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRAB#NASDAQ">GRAB</a>) gained 11.7% to $4.8990 after the company reported better-than-expected quarterly financial results and raised its FY25 revenue guidance above estimates.</li>
<li>Sea Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SE#NYSE">SE</a>) gained 10.8% to $108.00 after the company reported better-than-expected third-quarter sales, despite a miss on EPS estimates..</li>
<li>The Buckle, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKE#NYSE">BKE</a>) rose 5.4% to $47.57 after UBS upgraded the stock from Sell to Neutral and raised its price target from $31 to $46.</li>
<li>Live Nation Entertainment, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYV#NYSE">LYV</a>) gained 4.4% to $129.21 following third-quarter results. </li>
</ul>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41877638/jim-cramer-tech-stock-go-to-160-recommends-buying-dominos-pizza">Jim Cramer: This Tech Stock Can &#8216;Go To 160,&#8217; Recommends Buying Domino&#8217;s Pizza</a></li>
</ul>

Movers

ALIT

GRAB

NWTN

PRTH

RVNC

SHOP

Tyson Foods Posts Better-Than-Expected Earnings, Joins Shopify, Sea, Buckle And Other Big Stocks Moving Higher On Tuesday

Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) advocate and Morgan Creek Digital co-founder, Anthony Pompliano on Tuesday expressed unwavering confidence in Bitcoin&#8217;s long-term dominance despite market fluctuations, asserting that the apex crypto is the king of the <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41896277/bitcoin-nears-90000-how-high-can-the-apex-crypto-go">cryptocurrency market which will not die.</a>
What Happened: "Most kings are centralized&#8230;but the beauty of Bitcoin is that it's decentralized&#8230;It is rules without rulers,&#8221; he said in an <a href="https://www.foxbusiness.com/video/6364562625112">interview </a>with Fox News.
Pompliano will further discuss Bitcoin's potential at Benzinga&#8217;s <a href="https://www.benzinga.com/events/digital-assets/agenda/">Future of Digital Assets</a> event on Nov. 19.
While the past few years have humbled Pompliano regarding market predictions, his conviction in Bitcoin's future remains steadfast. In 2019, he boldly predicted Bitcoin would reach $100,000 within 2.5 years. 
Though the asset didn't reach that target, rising sixfold instead, Pompliano conceded that "price predictions are a fool&#8217;s game," admitting, <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41274733/in-2022-bitcoin-helped-to-humble-anthony-pompliano-a-look-at-how-his-price-predictions-hav">"Bitcoin helped to humble me."</a>
Despite this, he affirmed, "I haven't changed my mind on anything," continuing to buy Bitcoin both personally and professionally.
By 2023, Pompliano had renewed optimism, declaring on CNBC's Last Call that "Bitcoin and the crypto industry are not going anywhere." 
He acknowledged Bitcoin's cyclical nature, citing historical crashes and recoveries as evidence of its resilience. 
"Young people want these assets, and they're going to continue to buy," he said, anticipating a rally catalyzed by the 2024 Bitcoin halving, media attention, institutional interest, and <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41899968/bitcoin-etfs-post-record-1-1-billion-inflow-what-is-going-on">Bitcoin ETF approvals</a>.
Pompliano observed that institutional appetite for Bitcoin surged dramatically in 2024, with Wall Street firms investing heavily.
"Wall Street doesn't just like Bitcoin. They love Bitcoin," he stated, referencing the substantial inflows into Bitcoin ETFs by firms like BlackRock and Fidelity.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/ "><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/29155259/905735A6-57D3-4874-9AA1-75D037842DB3-2.gif" alt="Benzinga Future of Digital Assets conference" class="wp-image-270548" /></a></figure>
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41896277/bitcoin-nears-90000-how-high-can-the-apex-crypto-go">Bitcoin Nears $90,000—How High Can The Apex Crypto Go?</a>
Why It Matters: Looking to the future, Pompliano envisions significant growth for Bitcoin.
He recently suggested that Bitcoin could reach between $100,000 and $200,000 in the next 12 to 18 months, driven by supply-demand dynamics and the upcoming halving event, which he believes will further constrict Bitcoin's supply. 
&#8220;If this continues, that we have 12.5 times more demand… this thing's going back to its all-time high. It's pretty much guaranteed," he predicted.
Pompliano also highlighted Bitcoin's unique value as a hedge against inflation and the devaluation of fiat currencies, framing it as a key component of the global economy. 
He suggested that Bitcoin's role could become even more pronounced during shifts in monetary policy, especially as the Federal Reserve's recent interest rate cuts add liquidity that may benefit the crypto market.
Despite previous setbacks in his predictions, Pompliano's influence remains strong in the crypto community, making him a frequent speaker at industry events. 
His upcoming appearance at Benzinga&#8217;s <a href="https://www.benzinga.com/events/digital-assets/agenda/">Future of Digital Assets</a> event on Nov. 19 will delve deeper into Bitcoin's trajectory, the impact of global economic policies, and the next potential catalysts for the market.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/sports-betting/24/11/41889838/polymarket-bettors-say-60-likelihood-bitcoin-crosses-100k-this-year">Polymarket Bettors Say 60% Likelihood Bitcoin Crosses $100K This Year</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

Bitcoin Is The 'Decentralized King,' Says Anthony Pompliano, Whose $100,000 Price Prediction Is Close To Coming True

AMGN

Amgen shares are trading lower after Cantor Fitzgerald highlighted pipeline risks and a 4% BMD loss in its AMG-133 Phase 1 trial.

Federal Reserve

Fed's Kashkari Says Bar Of Stopping Fed Balance Sheet Runoff 'Quite High'; Fed Has A Ways To Go Before It Stops Shrinking Balance Sheet

Guidance

Cantor Fitzgerald Maintains Overweight Rating On Amgen With $405 Price Target, Projecting $33.2B Revenue In 2024; Highlights Pipeline Risks And -4% BMD Loss In AMG-133 Phase 1 Trial

ADC Therapeutics SA 2024 Q2 - Results - Earnings Call Presentation

Week In Review: UCB Sells China Drug Portfolio For $680 Million To CBC

ADC Therapeutics Ltd (ADCT) has disclosed a new risk, in the Innovation / R&D category. ADC Therapeutics Ltd faces considerable uncertainty with it...

ADC Therapeutics and the Perils of Outsourced Trials: Navigating the Uncertainty of ZYNLONTA's Phase 2 Study

ADC Therapeutics Non-GAAP EPS of -$0.28, revenue of $18.46M misses by $0.04M

Reports Q3 revenue $18M, consensus $18.46M. "We are excited about the advancements in our ZYNLONTA(R) trials in earlier lines of diffuse large B-ce...

ADC Therapeutics reports Q3 adjusted EPS (28c), consensus (39c)

Stephens initiated coverage of ADC Therapeutics (ADCT) with an Overweight rating and $6 price target Published first on TheFly – the ultimate sourc...

ADC Therapeutics initiated with an Overweight at Stephens

Stephens initiated coverage of ADC Therapeutics (ADCT) with an Overweight rating and $6 price target as the firm is adding to its biotechnology res...

ADC Therapeutics initiated with an Overweight at Stephens on Zynlonta potential

ADC Therapeutics Ltd ( ($ADCT) ) has released its Q3 earnings. Here is a breakdown of the information ADC Therapeutics Ltd presented to its investo...

ADC Therapeutics Highlights Q3 Advances and Strategic Focus

RBC Capital analyst Gregory Renza maintained a Buy rating on ADC Therapeutics (ADCT – Research Report) yesterday and set a price target of $8.00. T...

ADC Therapeutics (ADCT) Receives a Buy from RBC Capital

ADC Therapeutics SA (ADCT) Q3 2024 Earnings Call Transcript

ADCT

BEIGF

BGNE

BNTX

UCBJF

UCBJY

Press Releases

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

ADC Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update

ADC Therapeutics to Present at Upcoming Investor Conferences

ADC Therapeutics to Host Third Quarter 2024 Financial Results Conference Call on November 7, 2024

ADC Therapeutics to Present at November Investor Conferences

ADC Therapeutics Announces Investigator-Initiated Study Abstracts Accepted for Presentation at the 66th ASH Annual Meeting

ADC Therapeutics Reports Third Quarter and Year-to-Date 2024 Financial Results and Provides Operational Update

Comments

ADC Therapeutics

ニュース

最新ニュース ADC Therapeutics (NYSE:ADCT) 株価情報

ニュース

パートナーシップ

ベンジンガ・グローバル